Bachem Holding AG focuses on peptide manufacturing and global pharma demand

Bachem Holding AG (ISIN CH0012530207) is a Switzerland-based specialist in the development and manufacture of peptide and oligonucleotide active pharmaceutical ingredients for global drugmakers. The company is listed in Switzerland and serves biotechnology and pharmaceutical customers in North America, Europe and Asia as part of long-running supply and development agreements.

Peptide APIs for global pharma clients

Bachem Holding AG positions itself as a contract development and manufacturing organization with a focus on complex peptide and oligonucleotide active pharmaceutical ingredients used in branded and generic medicines. Its customers include large and mid-sized pharmaceutical companies as well as research-driven biotechnology firms that rely on external manufacturing partners to scale clinically validated compounds into commercial production.

The company operates multiple production sites with capabilities for large-scale solid phase peptide synthesis and downstream purification, which are essential for high-purity ingredients used in injectable therapies and other dosage forms. These facilities are subject to international quality standards applicable to active pharmaceutical ingredients, such as good manufacturing practice requirements enforced by health authorities in major markets.

Regulated markets and long-term contracts

Because peptide and oligonucleotide medicines are often developed for chronic conditions or specialized indications, manufacturing contracts can extend over many years once a compound is approved. Bachem Holding AG benefits from recurring demand for established active ingredients while also participating in earlier-stage development work where volumes are smaller but technical requirements are high.

The company reports revenue streams from commercial APIs, clinical development projects and custom synthesis services. Commercial APIs typically provide more predictable volumes when originator drugs or generics have stable demand, while project-based work is influenced by the pace of drug development pipelines and regulatory submissions in markets such as the United States, Europe and Japan.

Representative peptide product portfolio

As a manufacturer of peptide active ingredients, Bachem Holding AG supports a range of therapeutic areas, including metabolic diseases, oncology and rare conditions, where peptide-based drugs play an important role. The company offers catalog products for research and clinical use as well as custom synthesis services for proprietary molecules under development by its customers.

Bachem Holding AG stock and listing

Bachem Holding AG is listed on the Swiss market, where its shares reflect expectations about demand for peptide and oligonucleotide ingredients, the pace of clinical development projects and broader sentiment toward contract manufacturing in the life sciences sector.

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.